{"title": "PDF", "author": "PDF", "url": "assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/934360/Data_Briefing_Slides_11112020.pdf", "hostname": "PDF", "description": "PDF", "sitename": "PDF", "date": "PDF", "cleaned_text": "Phase I Small numbers, Safety, Dosage,Regulatory ReviewLarge Scale Production and DistributionClinical Trials Phase II Immune responsePhase III Protection against disease Several years Traditional Vaccine Development Timeline Safety assessment ongoing throughoutClinical Trial AuthorisationProcess development, preclinical & toxicology studies Design & exploratory preclinical studiesPhase I Rolling Regulatory Review Large Scale Production (At Risk) 10 months +Clinical Trials (months) Phase II Phase IIIClinical Trial AuthorisationProcess development, preclinical & toxicology studies (months)Design & exploratory preclinical studies (months)SARS -CoV-2 Accelerated Vaccine Development Timeline Safety assessment ongoing throughout Overlapping Clinical TrialsAt Risk ManufacturingVaccines with UK agreements Vaccine Type Description Vaccine Developer mRNA Sends a coded message to the immune system to make COVID antibodies BioNTech/Pfizer Adenoviral VectorCOVID spike protein inserted inside a harmless weakened common cold virusOxford/AstraZeneca Janssen Protein Adjuvant Broken up pieces of COVID proteins stimulate antibody productionNovavax GlaxoSmithKline/ Sanofi Pasteur Inactivated Whole Virus The whole "}